Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia (NCT07473713) | Clinical Trial Compass
RecruitingPhase 1
Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia
United States60 participantsStarted 2026-04-15
Plain-language summary
The goal of this clinical trial is to learn if veverimer will reduce urinary net acid excretion leading to reduced bone resorption in healthy adults with osteopenia. The main questions it aims to answer are:
* How much does each dose of veverimer (vs. placebo) reduce 24-hr urinary net acid excretion.
* Describe the safety of veverimer based on changes in serum bicarbonate and potassium.
* Assess the changes in bone resorption.
* Assess the changes in bone formation.
* Explore the effect of veverimer on physical performance.
Participants will:
* Take veverimer or placebo every day or every other day for 8 weeks
* Visit the clinic a total of 8 times (including screening) for checkups and testing
* Keep a medication diary tracking each day they take the study drug
Who can participate
Age range
50 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Community dwelling adults age 50 years and older (approximately equal numbers of men and women).
. Men should be sterile or agree to use contraception throughout the study.
. Women must be postmenopausal, defined as no menses in the last 5 years (to reduce variability in change in bone resorption since menopause prompts a rapid increase in bone resorption).
. Osteopenia will be defined as a bone mineral density (BMD) T-score at the lumbar spine, femoral neck, or total hip lower than -1 or higher than -2.5.
. On a prescreening interview, candidates must report a usual diet associated with an acid load by our validated short questionnaire.
. Estimated glomerular filtration rate (eGFR) must be 45 ml/min or greater.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
24-hr urinary net acid excretion
Timeframe: measured at screening, week 2, week 8 and week 8 +1day
. Participants must agree not to change their exercise pattern or medication use during the study.
. Participants must agree not to change their pattern of supplement use and not to use antacids during the study because most calcium supplements and other antacids add alkali.
Exclusion criteria
. Normal BMD T-scores at all spine and hip sites, osteoporosis based on BMD T-score of -2.5 or less